30 closest matches · ranked by relevance
Multisystem Inflammatory Syndrome-Children
Primary: Number of Participants Needing Additional Anti-inflammatory Therapy Within the First Week of First Randomization — 10; 10; 14 Participants
Mucocutaneous Lymph Node Syndrome
Primary: Number of Participants With Cessation of Fever Within 24h of Initiation of Study Treatment With no Fever Recurrence Within Next 7 Days. — 25; 40 Participants
Kawasaki Disease
Primary: Number of Adverse Events (Focused on Side Effects From IVIG or Infliximab Administration) — 2; 3 events
COVID-19 · Myocardial Reperfusion Injury · Cardiovascular Diseases
Primary: Number of Death — 417; 137; 552 Participants
Kawasaki Disease
Primary: Number of Participants With Adverse Events — 2; 3; 13 participants
Kawasaki Disease
Primary: The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion — 11; 11…
Pediatric Sepsis-induced MODS
Primary: Number of Subjects With Restoration of the TNF-alpha Response — 10; 8 Participants
Macrophage Activation Syndrome · Secondary Hemophagocytic Lymphohistiocytosis · Still Disease
Primary: Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab — 11; 4 Participants
Macrophage Activation Syndrome · Lymphohistiocytosis, Hemophagocytic · Arthritis, Juvenile
Primary: Incidence, Severity, Causality, and Outcomes of AEs (Serious and Nonserious) — 13; 6; 2; 10 Participants
Muckle Wells Syndrome
Primary: Percent of Participants With Disease Flare in Part II (After 24 Weeks of the Double-blind Part) — 0; 81.3 percent of participants
Congenital Heart Disease in Children · Inflammatory Response
Primary: Number of Participants at Each Global Rank Endpoint Based Upon Their Most-severe Outcome — 12; 17; 3; 7 Participants — p=0.14
Covid19 · Multisystem Inflammatory Syndrome in Children (MIS-C)
Primary: Estimate the Proportion of Patients With Normal Perfusion Versus Area(s) of Hypoperfusion in Heart, Kidneys and/or Brain — 2; 1 Participants
Influenza
Primary: Number of Patients With Clinical Phenotype Presenting Also a Sequential Activation of Immune/Infammatory Pathways. — 131 Participants
Cryopyrin-associated Periodic Syndromes · Familial Cold Autoinflammatory Syndrome · Muckle-Wells Syndrome
Primary: Percentage of Participants Aged 4 Years or Younger With at Least One Complete Response at Week 56 — 94.1 Percentage of participants
Asthma
Primary: Rate of Exacerbations Requiring Systemic Corticosteroids — 0.97; 0.95 events per years of follow-up
Children With Medical Complexity (CMC) · COVID-19
Primary: Change in Protocol Uptake: Number of Children and Staff Consented Compared to Number of Approached — 71; 17 Participants
Sepsis
Primary: Longitudinal Change Over Time in Cell Types and Pro and Anti Inflammatory Cytokines in Sepsis. — 14; 12 participants
Mood Disorder · Mental Disorder Diagnosed in Childhood · Attention Deficit and Disruptive Behavior Disorder
Primary: Percentage of Participants That "Much Improved" (Score of 2) in, or "Completely Recovered" (Score of 1) From Their Irritability Severity, as Measured With the Clinical…
Influenza · Influenza Immunisation
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) — 0; 0 Participants
Inflammatory Bowel Disease
Primary: Pediatric INTERMED- Complexity Index — 24; 9.0; 4.0; 4.0 scores on a scale
IBD
Primary: Diagnostic Yield of Magnetic Resonance Enterography (MRE) — 52 % Percentage of Diagnostic yeild
Ulcerative Colitis
Primary: Pharmacokinetics (PK): Clearance of Mirikizumab — 0.000190 Liters per hour per kilogram (L/hr/kg)
Fever After Vaccination · Fever · Seizures Fever
Primary: Number of Participants With Fever Following Vaccination — 14; 10 Participants
Ulcerative Colitis
Primary: Number of Participants With Clinical Response During Double-Blind Acute Phase at Week 8 — 10; 17 Participants — p=0.039
Ulcerative Colitis
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) of MMX Mesalamine (5-ASA) at Steady State — 21411; 46173; 49213 ug*h/L
Inflammatory Bowel Diseases
Primary: Number of Subjects Who Experience Serious Adverse Events, Adverse Events, and/or Early Treatment Discontinuations. — 1 Participants
Sickle Cell Disease
Primary: Rates of Recruitment — 14 weeks
Influenza · Otitis Media · Lower Resp Tract Infection
Primary: Hospitalization — 26; 2 Participants
Oesophagitis, Eosinophilic
Primary: Number of Participants With Any Adverse Events (AE), Any Serious Adverse Event (SAE) and Drug-related AE During Treatment Phase (TP) and Follow-up Phase (FP) — 18; 15…
Severe Acute Respiratory Syndrome (SARS) Pneumonia · Coronavirus Infections · ARDS, Human
Primary: Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28 — 19; 40 Participants